© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 4, 302-307,
February 19, 2003
© 2003 Oxford University Press
ARTICLE |
Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer
Affiliations of authors: E. Tan-Chiu, Cancer Research Network, Plantation, FL; J. Wang, J. P. Costantino, C. Butch (Biostatistical Center), S. Paik (Division of Pathology), D. L. Wickerham, B. Fisher, N. Wolmark (Operations Center), National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA.
Correspondence to: Elizabeth Tan-Chiu, M.D., Cancer Research Network, 350 84th Ave., Suite 305, Plantation, FL 33324 (e-mail: tan-chiu{at}att.net).
Background: In 1998 the National Surgical Adjuvant Breast and Bowel Project (NSABP) demonstrated that tamoxifen treatment reduced the incidence of both invasive and noninvasive breast cancer in women at high risk for the disease. We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women. Methods: We examined the medical records of 13 203 women with follow-up who participated in the NSABP Breast Cancer Prevention Trial. Included in this analysis were women who had undergone a breast biopsy and who had histologic diagnoses of adenosis, cyst, duct ectasia, fibrocystic disease, fibroadenoma, fibrosis, hyperplasia, or metaplasia. The relative risk (RR) for each histologic diagnosis was estimated for women who received tamoxifen and for women who received placebo. We also tallied the number of biopsies that women in the placebo and tamoxifen groups underwent. Results: Overall, tamoxifen treatment reduced the risk of benign breast disease by 28% (RR = 0.72, 95% confidence interval [CI] = 0.65 to 0.79). Tamoxifen therapy resulted in statistically significant reductions in the risk of adenosis (RR = 0.59, 95% CI = 0.47 to 0.73), cyst (RR = 0.66, 95% CI = 0.58 to 0.75), duct ectasia (RR = 0.72, 95% CI = 0.53 to 0.97), fibrocystic disease (RR = 0.67, 95% CI = 0.58 to 0.77), hyperplasia (RR = 0.60, 95% CI = 0.50 to 0.71), and metaplasia (RR = 0.51, 95% CI = 0.41 to 0.62). Tamoxifen therapy also reduced the risk for fibroadenoma (RR = 0.77, 95% CI = 0.56 to 1.04) and fibrosis (RR = 0.86, 95% CI = 0.72 to 1.03). Compared with the placebo group, the tamoxifen group had 29% (95% CI = 23% to 34%) fewer biopsies (1048 versus 1469) and 19% fewer women who underwent a biopsy (811 versus 1019). This resulted in a 29% reduction in the risk of biopsy in women treated with tamoxifen (RR = 0.71, 95% CI = 0.66 to 0.77). This risk reduction occurred predominantly in women younger than 50 years. Conclusion: Women in this study who received tamoxifen, especially younger women (i.e., <50 years), had a reduced incidence of clinically detected benign breast disease and underwent fewer breast biopsies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. E. Rohan, A. Negassa, R. T. Chlebowski, L. Habel, A. McTiernan, M. Ginsberg, S. Wassertheil-Smoller, and D. L. Page Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial J Natl Cancer Inst, April 16, 2008; 100(8): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Poola, B. Shokrani, R. Bhatnagar, R. L. DeWitty, Q. Yue, and G. Bonney Expression of Carcinoembryonic Antigen Cell Adhesion Molecule 6 Oncoprotein in Atypical Ductal Hyperplastic Tissues Is Associated with the Development of Invasive Breast Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4773 - 4783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cazzaniga, G. Severi, C. Casadio, L. Chiapparini, U. Veronesi, and A. Decensi Atypia and ki-67 expression from ductal lavage in women at different risk for breast cancer. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1311 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Santen and R. Mansel Benign Breast Disorders N. Engl. J. Med., July 21, 2005; 353(3): 275 - 285. [Full Text] [PDF]
|
|
|
|
|
|
C. Schairer, D. Hill, S. R. Sturgeon, T. Fears, C. Mies, R. G. Ziegler, R. N. Hoover, and M. E. Sherman Serum Concentrations of Estrogens, Sex Hormone Binding Globulin, and Androgens and Risk of Breast Hyperplasia in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1660 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kudachadkar and R. M. O'Regan Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer CA Cancer J Clin, May 1, 2005; 55(3): 145 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Muller-Decker, I. Berger, K. Ackermann, V. Ehemann, S. Zoubova, S. Aulmann, W. Pyerin, and G. Furstenberger Cystic Duct Dilatations and Proliferative Epithelial Lesions in Mouse Mammary Glands upon Keratin 5 Promoter-Driven Overexpression of Cyclooxygenase-2 Am. J. Pathol., February 1, 2005; 166(2): 575 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Stearns, A. Gallagher, C. G. Kleer, B. Singh, M. Freedman, B. R. Haddad, C. Isaacs, R. Warren, M. Brown, J. Cullen, et al. A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity Clin. Cancer Res., December 15, 2004; 10(24): 8332 - 8340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Ford, M. Faedo, R. Crouch, J. S. Lawson, and W. D. Rawlinson Progression from Normal Breast Pathology to Breast Cancer Is Associated with Increasing Prevalence of Mouse Mammary Tumor Virus-Like Sequences in Men and Women Cancer Res., July 15, 2004; 64(14): 4755 - 4759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lu, S. K. Mohsin, S. Hilsenbeck, A. Wakeling, and P. H. Brown RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors J Natl Cancer Inst, May 5, 2004; 96(9): 715 - 716. [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, March 1, 2003; 326(7387): 508 - 508. [Full Text] [PDF]
|
|